-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, the Ningxia Medical Insurance Bureau publicly solicited opinions on the "Implementation Plan for the Bargaining and Purchasing of Medicines and Medical Consumables for Medical Institutions in Ningxia Hui Autonomous Region (Trial)"
.
It is understood that it is clear in the plan that according to the evaluation of the pilot direct settlement between the medical insurance fund and the enterprise, it will be explored to include the medical consumables in the medical insurance catalogue purchased by the alliance into the scope of direct settlement in a timely manner
.
For medical consumables not included in the medical insurance catalogue, medical institutions and enterprises shall settle the payment in time, and the settlement time shall not exceed the end of the next month after the delivery is accepted
.
In this regard, the industry generally believes that it is a good thing for pharmaceutical companies that medical insurance can directly settle the payment for drug companies
.
In recent years, under the background that the centralized procurement of medicines and consumables has continuously compressed the profit space of enterprises, a large number of enterprises have faced great pressure on cash turnover
.
Once the medical institution does not return the payment in time, it will have a greater impact on the operation of the enterprise
.
It is reported that many hospitals in Shandong have had problems with arrears of drug payments
.
The Shandong Provincial Medical Insurance Bureau and the Health and Health Commission notified in March 2021 that 89 primary medical and health institutions in 14 counties (cities, districts) in seven cities including Jinan, Zibo, Jining, Tai'an, Linyi, Liaocheng, and Heze still owe the payment of 2020 Before March 31, 2009, pharmaceutical companies are required to increase the payment of drug payments and complete the task of clearing the debt as soon as possible
.
In addition, in September 2018, the Hubei Provincial Pharmaceutical Industry Association investigated 8 representative pharmaceutical commercial enterprises.
The results showed that the payment period for medicines in public medical institutions was as long as 960 days, and the amount of arrears was as high as 86 million yuan
.
In addition, the average billing period of a public hospital at level two or above in a certain province is about 640 days, and the total arrears of a commercial company for drugs is as high as 280 million yuan
.
In order to solve this problem, in recent years, the state has been rectifying the problem that medical institutions have difficulty in collecting payment, and has issued a series of documents to continuously increase the supervision of payment settlement by medical institutions
.
For example, as early as March 2020, the "Opinions on Deepening the Reform of the Medical Insurance System" clearly stated that "promoting the direct settlement of medical insurance funds and pharmaceutical companies"
.
In May, the National Medical Insurance Administration issued the "Notice on Printing and Distributing the List of Government Services Items for National Medical Security Handling", which also clearly specified that the time limit for the settlement of medical institutions (including medical institutions and retail pharmacies) should not exceed 30 working days
.
At present, with the help of national policies, various regions have begun to accelerate the direct settlement of medical insurance
.
In addition to Ningxia, on August 10, the Xiamen Municipal Medical Insurance Bureau, the Health and Health Commission and the Market Supervision Administration also jointly issued the "Work Plan on Implementing the Centralized Procurement of General Medical Consumables in Xiamen Public Medical Institutions" (hereinafter referred to as the "Plan") notice
.
The new plan proposes that, in order to ensure the timely settlement of the payment for goods, the payment for the products selected by the general consumption centralized procurement will be included in the scope of medical insurance payment.
Product payment
.
The payment for products paid by the medical insurance fund is deducted from the medical insurance settlement of medical institutions, and the authority to settle the payment for consumables of medical institutions is completely cancelled
.
In addition, Shandong, Shaanxi, Guizhou, Tianjin, Liaoning, Henan and other places have also launched pilot projects to promote direct settlement between medical insurance funds and enterprises
.
In this regard, the industry believes that under the background that the country and localities strictly rectify the difficulty of medical institutions in collecting payment and continue to promote the connection between payment and medical insurance, the pressure of payment of pharmaceutical companies and equipment companies will be further reduced, which will be conducive to China's pharmaceutical and medical equipment industries will develop more healthily and orderly in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is understood that it is clear in the plan that according to the evaluation of the pilot direct settlement between the medical insurance fund and the enterprise, it will be explored to include the medical consumables in the medical insurance catalogue purchased by the alliance into the scope of direct settlement in a timely manner
.
For medical consumables not included in the medical insurance catalogue, medical institutions and enterprises shall settle the payment in time, and the settlement time shall not exceed the end of the next month after the delivery is accepted
.
In this regard, the industry generally believes that it is a good thing for pharmaceutical companies that medical insurance can directly settle the payment for drug companies
.
In recent years, under the background that the centralized procurement of medicines and consumables has continuously compressed the profit space of enterprises, a large number of enterprises have faced great pressure on cash turnover
.
Once the medical institution does not return the payment in time, it will have a greater impact on the operation of the enterprise
.
It is reported that many hospitals in Shandong have had problems with arrears of drug payments
.
The Shandong Provincial Medical Insurance Bureau and the Health and Health Commission notified in March 2021 that 89 primary medical and health institutions in 14 counties (cities, districts) in seven cities including Jinan, Zibo, Jining, Tai'an, Linyi, Liaocheng, and Heze still owe the payment of 2020 Before March 31, 2009, pharmaceutical companies are required to increase the payment of drug payments and complete the task of clearing the debt as soon as possible
.
In addition, in September 2018, the Hubei Provincial Pharmaceutical Industry Association investigated 8 representative pharmaceutical commercial enterprises.
The results showed that the payment period for medicines in public medical institutions was as long as 960 days, and the amount of arrears was as high as 86 million yuan
.
In addition, the average billing period of a public hospital at level two or above in a certain province is about 640 days, and the total arrears of a commercial company for drugs is as high as 280 million yuan
.
In order to solve this problem, in recent years, the state has been rectifying the problem that medical institutions have difficulty in collecting payment, and has issued a series of documents to continuously increase the supervision of payment settlement by medical institutions
.
For example, as early as March 2020, the "Opinions on Deepening the Reform of the Medical Insurance System" clearly stated that "promoting the direct settlement of medical insurance funds and pharmaceutical companies"
.
In May, the National Medical Insurance Administration issued the "Notice on Printing and Distributing the List of Government Services Items for National Medical Security Handling", which also clearly specified that the time limit for the settlement of medical institutions (including medical institutions and retail pharmacies) should not exceed 30 working days
.
At present, with the help of national policies, various regions have begun to accelerate the direct settlement of medical insurance
.
In addition to Ningxia, on August 10, the Xiamen Municipal Medical Insurance Bureau, the Health and Health Commission and the Market Supervision Administration also jointly issued the "Work Plan on Implementing the Centralized Procurement of General Medical Consumables in Xiamen Public Medical Institutions" (hereinafter referred to as the "Plan") notice
.
The new plan proposes that, in order to ensure the timely settlement of the payment for goods, the payment for the products selected by the general consumption centralized procurement will be included in the scope of medical insurance payment.
Product payment
.
The payment for products paid by the medical insurance fund is deducted from the medical insurance settlement of medical institutions, and the authority to settle the payment for consumables of medical institutions is completely cancelled
.
In addition, Shandong, Shaanxi, Guizhou, Tianjin, Liaoning, Henan and other places have also launched pilot projects to promote direct settlement between medical insurance funds and enterprises
.
In this regard, the industry believes that under the background that the country and localities strictly rectify the difficulty of medical institutions in collecting payment and continue to promote the connection between payment and medical insurance, the pressure of payment of pharmaceutical companies and equipment companies will be further reduced, which will be conducive to China's pharmaceutical and medical equipment industries will develop more healthily and orderly in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
